InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Advances ADI-100 Autoimmune Therapy Toward Clinical Trials
Aditxt (NASDAQ: ADTX) provided an update on its subsidiary, Adimune, Inc., and the progress of ADI-100, an investigational gene therapy targeting autoimmune diseases such as psoriasis, Type 1 diabetes, and Stiff Person Syndrome. Adimune has completed preclinical studies and is preparing for drug substance shipment in March, with clinical trials planned in Germany and an FDA pre-IND meeting anticipated in the second quarter of 2024.…